Agenda
Introduction and Overview
Importance of Optimal Treatment for HER2-Positive Breast Cancer and Giving Treatment With Compassion
Localized HER2-Positive Breast Cancer: A Brief Review of Relevant Data With Case Challenges for Discussion
HER2-Positive Metastatic Breast Cancer: A Brief Review of Relevant Data With Case Challenges for Discussion
“Putting It All Together”: Integrating Guideline Updates, New Clinical Data, and Patient Treatment Goals and Preferences
Personalized Treatment Planning: A Case-Based Discussion
Final Thoughts
Events
Date / Time
Event Details
Faculty
Faculty
Aditya Bardia, MD, MPH
Director, Breast Cancer Research
Associate Professor
Harvard Medical School
Attending Physician
Massachusetts General Hospital
Boston, Massachusetts
Faculty
Sara Hurvitz, MD, FACP
Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
Faculty
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN
Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana
Faculty
Danielle Roman, PharmD, BCOP
Manager, Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania
Goal Statement
The goal of this activity is to educate oncologists, oncology nurses, pharmacists, and other healthcare professionals about recent developments in the care of HER2-positive breast cancer to optimally individualize therapy for this patient population.
Target Audience
This educational program is intended for oncologists, advanced practice clinicians, oncology nurses, navigators, pharmacists, and other supportive services and their patients with HER2-positive breast cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Address gaps in patient-provider knowledge and perceptions about current and emerging treatment options for HER2-positive breast cancer
- Foster collaborative discussions between patients/caregivers and providers on guidelines and recent clinical evidence to guide personalized treatment planning for HER2-positive breast cancer
- Implement resources to engage patients in shared decision-making about treatment for HER2-positive breast cancer
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-048-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.